Article
circSTIL mediates pirarubicin inhibiting the malignant phenotype of triple-negative breast cancer and acts as a biomarker in plasma exosomes.
Molecular immunology - 1 Apr 2025
Ji Jiahua, Li Min, Yan Kaixu, Ma Jiulong, Wei Dexian, Zhang Fan, Qiao Sennan, Huang Peng, Zhang Wenqing, Li Lu, Zheng Wentao, Ren Liqun
Abstract excerpt
In clinical practice, pirarubicin (THP) is a widely used triple-negative breast cancer (TNBC) agent. It has been found that circular RNAs (circRNAs) are involved in cancer treatment and progression. However, the biological function of circRNAs in TNBC and the relationship between THP and circRNAs remain poorly studied. circSTIL (hsa_circ_0000069) was screened and validated by bioinformatics analysis,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
